Our perspectives
in one place
Topic
Selected filters
Clear
News
See allStatement at the fourth meeting of the open-ended Intergovernmental Working Group (IGWG 4) on the WHO Pandemic Agreement
On 1st December 2025 in Geneva, IFPMA delivered a statement at at the fourth meeting of the open-ended Intergovernmental Working Group (IGWG 4) on the WHO Pandemic Agreement.
Read moreWIPO Committee on IP and Development (CDIP 35): Technology Transfer
On 20 November 2025, IFPMA submitted a statement on technology transfer at the WIPO Committee on IP and Development (CDIP 35) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which...
Read moreBiopharmaceutical CEOs Roundtable met in Berlin
12 NOVEMBER 2025, Berlin – The Biopharmaceutical CEOs Roundtable (BCR), a global policy platform representing the world’s leading biopharmaceutical companies, convened last week in Berlin to discuss how pharmaceutical innovation can drive better health outcomes, strengthen economies, and enhance global health security. The BCR delegation also met with Federal Chancellor Merz, along with key members...
Read moreWIPO Standing Committee on Patents (SCP 37): Technology Transfer
On 5 November 2025, IFPMA delivered a statement on technology transfer at the WIPO Standing Committee on Patents (SCP 37) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which is...
Read moreWIPO Standing Committee on Patents (SCP 37): Patents and health
On 4 November 2025, IFPMA delivered a statement on patents and health at the WIPO Standing Committee on Patents (SCP 37) in Geneva. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global research-based biopharmaceutical industry. We appreciate the opportunity to address the Committee on patents and health. Intellectual property is fundamental to...
Read moreStatement on PABS Instrument at the third meeting of the open-ended Intergovernmental Working Group (IGWG 3) on the WHO Pandemic Agreement
On 3 November 2025 in Geneva, IFPMA delivered a statement at at the tnird meeting of the open-ended Intergovernmental Working Group (IGWG 3) on the WHO Pandemic Agreement.
Read morePublications
See allThe innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines
IFPMA introduces the “Innovation Development and Access Pathway” (IDAP), a framework designed to build a shared understanding of the end-to-end pathway of how medicines and vaccines move from discovery to delivery at the point of care. The paper maps the four critical pillars of this journey: R&D and the innovation ecosystem; regulatory processes and life cycle management; listing, procurement and reimbursement; and health service delivery. It identifies systemic challenges, and proposes collaborative solutions to overcome them, and shows that improving access requires coordinated action across stakeholders, with governments playing a central role in enabling timely and equitable access to innovation.
Read more
The role of assessment reports in enabling regulatory reliance – perspectives from the pharmaceutical industry
Reliance in decision-making offers a pathway for national regulatory authorities (NRAs) to consider evaluations conducted by other NRAs while maintaining accountability for their decisions. By avoiding duplicative reviews and optimizing resource allocation, the use of regulatory reliance can lead to faster patient access to safe, effective, and high-quality medical products in a timely manner. A...
Read more
Best practices for unilateral reliance for initial marketing authorization and post-approval changes
Regulatory reliance has emerged as a key strategy for strengthening regulatory systems by optimizing resources, reducing duplication, and accelerating access to high-quality medicines. By leveraging the expertise and prior decisions of trusted national regulatory authorities (NRAs), reliance allows NRAs to focus their efforts on critical public health priorities while maintaining sovereignty over final regulatory decisions....
Read more
Expert insights
See all
A new dawn in global health: UHC as the path toward national health stewardship
Read more
Health as an economic priority – building on momentum driven by the G20 South Africa Presidency
Read more
Getting procurement right: sustainable and secure supply chains that support access to medicines
Read moreResources
See allStreamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more
Our Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more